Generic Name and Formulations:
Fluocinolone acetonide 0.19mg; implant for intravitreal inj.
Diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids without a significant rise in intraocular pressure.
Give by intravitreal inj. See full labeling for administration.
Ocular or periocular infections. Glaucoma.
Monitor for increased intraocular pressure and endophthalmitis; may include check for perfusion of the optic nerve head immediately, tonometry within 30 mins, and biomicroscopy between 2–7 days post inj. Risk of secondary ocular infections (eg, bacterial, fungal, viral). History of ocular herpes simplex: not recommended. Risk of implant migration if absent or torn posterior capsule of the lens. Pregnancy (Cat.C). Nursing mothers.
Cataract development, increased intraocular pressure; injection-related effects (eg, endophthalmitis, eye inflammation, retinal detachments), others.
Single-use applicator—1 (w. needle)
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...